中国医学前沿杂志（电子版）2017，Vol.9Issue(1)：59-64,6.DOI:10.12037/YXQY.2017.01-09
左、右半结肠癌的药物治疗现状及展望
Current status and perspective of drug treatment on left-side and right-side colon cancer
王晰程 1韦青 1沈琳1
作者信息
- 1. 北京大学肿瘤医院暨北京市肿瘤防治研究所 消化肿瘤内科 恶性肿瘤发病机制及转化研究教育部重点实验室,北京 100142
- 折叠
摘要
Abstract
Currently, increasing evidence indicates that left-side colon cancer and right-side colon cancer have distinguished prognosis. Regarding to drug treatment, left-side colon cancer with wild-type RAS gene is more likely to benefit from EGFR-Ab treatment. By contrast, right-side colon cancer seems less sensitive to response to standard chemotherapy and target therapy. Besides RAS gene status and primary tumor location, how to enrich patients sensitive to EGFR-Ab treatment is still an unsolved question. Recent studies suggest that BRAF mutation, HER2 amplification and low expression of EGFR ligand are negatively predictive factors to EGFR-Ab treatment. Is there any strategy to improve the prognosis of right-side colon cancer? There are high rates of MSI-H, BRAF mutation and RAS mutations in right-side colon cancer. In the future, we are dependent on drugs targeting these biomarkers in combination with new therapeutic methods to improve the treatment efficacy of right-side colon cancer.关键词
结肠癌/EGFR单抗/靶向治疗/免疫治疗Key words
Colon cancer/EGFR-Ab/Targeted therapy/Immunotherapy引用本文复制引用
王晰程,韦青,沈琳..左、右半结肠癌的药物治疗现状及展望[J].中国医学前沿杂志（电子版）,2017,9(1):59-64,6.
